Dermatology
News from the FDA/CDC
FDA approves two JAK-1 inhibitors for moderate to severe atopic dermatitis
“It’s big news because a few years ago we didn’t have any systemic treatments that are safer than the classical immunosuppressants.”
Opinion
75-year-old White male presenting with progressive pruritus and a worsening rash
A man with dermatitis herpetiformis, well controlled on dapsone, presented with progressive pruritus and a worsening rash.
Latest News
Hand eczema and atopic dermatitis closely linked
“As clinicians, we sometimes need to rule out a few differentials, including psoriasis and T-cell lymphoma,” Dr. Jacob P. Thyssen said.
From the Journals
Proactive infliximab monitoring found best for sustaining control of inflammatory diseases
Proactive therapeutic drug monitoring with maintenance infliximab proved more effective in sustaining disease control than did standard care in...
Conference Coverage
Key questions to ask atopic dermatitis patients with sleep complaints
Assessment tools to consider are the Epworth Sleepiness Scale, the Insomnia Severity Index, and the STOP-Bang questionnaire.
Latest News
Soon-to-be medical student awarded $10K after spotting melanoma
“The mole on the back of your neck is possibly cancerous. Please go see a doctor!”
Conference Coverage
Longitudinal course of atopic dermatitis often overlooked, expert says
“Understanding the long-term course may improve our ability to phenotype, prognosticate, and personalize our care,” Dr. Raj Chovatiya said.
Conference Coverage
Itch-dominant atopic dermatitis often flies under the radar
A disconnect often exists between clinician-reported and patient-reported outcome measures, says Dr. Jonathan Silverberg.
From the Journals
Case series show no consensus on treatment for palmoplantar pustulosis, generalized pustular psoriasis
“These case series confirm the rarity of both generalized pustular psoriasis and palmoplantar pustulosis ... and the lack of effective treatment...
Conference Coverage
Atopic dermatitis can be especially burdensome in the elderly
There is good data on higher relative risk of osteoporosis/fractures and dementia specifically among older adults with AD.
Latest News
FDA to review PDE4-inhibitor roflumilast for psoriasis
The target action date for approval for the topical psoriasis treatment is in July 2022.